☆ 4.3 Article

Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients

Takao Takeshima et al.

Summary: This study aimed to explore the onset of action of fremanezumab in Japanese and Korean migraine patients. The results showed that fremanezumab could reduce the frequency of migraine attacks from the first week after the initial injection, indicating an early onset of action.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Article Clinical Neurology

Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

Raffaele Ornello et al.

Summary: This study aimed to compare the relative and absolute efficacy of erenumab, and found that even patients with good relative response to erenumab may have a clinically non-negligible residual migraine burden.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Review Clinical Neurology

The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates

Lars Jacob Stovner et al.

Summary: This article summarizes the epidemiological studies of headache disorders globally, finding that headache disorders remain highly prevalent worldwide, and identifies methodological factors explaining the large variation between study findings. While migraine prevalence estimates increased over time, estimates for all headache types varied between world regions.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Review Clinical Neurology

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update

Simona Sacco et al.

Summary: This guideline evaluated the effectiveness and safety of monoclonal antibodies targeting the CGRP pathway for migraine prevention through systematic review and literature analysis, and provided updated treatment recommendations.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Review Clinical Neurology

The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine

Simona Guerzoni et al.

Summary: Chronic migraine is a challenge for physicians, and despite the introduction of monoclonal antibodies targeting CGRP, some patients still do not experience complete relief. The combination of onabotulinumtoxinA and anti-CGRP mAbs may offer a reliable option for these patients. However, there is limited evidence and regulatory restrictions regarding this combination therapy, calling for further well-designed studies and pharmacoeconomic analysis.

NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Deprescribing in migraine

Paolo Martelletti et al.

EXPERT OPINION ON DRUG SAFETY (2021)

添加到收藏夹

Article Clinical Neurology

Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance

Simona Sacco et al.

Summary: The study found that resistant and refractory migraine patients are commonly seen in clinical practice, but many physicians lack confidence in managing them. Patients are often not referred to more specialized centers, indicating unmet needs in the field.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

Todd J. Schwedt et al.

Summary: In patients who had not previously benefited from multiple migraine preventive treatments, galcanezumab demonstrated significant reduction in migraine headache days starting from the second month of treatment, indicating an early onset of therapeutic effect.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients

Raffaele Ornello et al.

Summary: The response to BT-A is significant in both men and women with a small gender difference in favor of women. Men tended to stop the treatment more frequently than women. More gender-specific data on migraine treatments are needed from randomized controlled trials and observational studies.

PAIN AND THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

Raffaele Ornello et al.

Summary: The study found that patients with chronic migraine who responded well or partially to BT-A in the first two treatment cycles were likely to benefit from a third cycle. However, the likelihood of non-responders in the first two cycles starting to respond in the third cycle was low. These results can help guide decisions on continuing or discontinuing treatment for patients who have not responded in the initial cycles.

PAIN AND THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

CGRP release in an experimental human trigeminal pain model

Achim Frese et al.

Summary: The study found that healthy subjects showed a significant increase in alpha-calcitonin-gene related peptide levels only after injection of capsaicin in the forehead, which suggests that this elevation is not specific to primary headache attacks but may be a non-specific effect of first trigeminal branch stimulation following pain activation.

CEPHALALGIA (2021)

添加到收藏夹

Article Food Science & Technology

Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA

Enrique Martinez-Pias et al.

Summary: Chronic migraine patients with daily headaches do not have a worse response to OnabotulinumtoxinA treatment, while patients with higher headache frequency at baseline are more likely to show a better response to this treatment.

TOXINS (2021)

添加到收藏夹

Article Economics

Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK

Georgia Hollier-Hann et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

添加到收藏夹

Article Clinical Neurology

Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study

Alicia Alpuente et al.

HEADACHE (2020)

添加到收藏夹

Article Clinical Neurology

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Raffaele Ornello et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Review Clinical Neurology

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

Rami Burstein et al.

HEADACHE (2020)

添加到收藏夹

Article Clinical Neurology

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

Antonio Russo et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Article Clinical Neurology

A prospective real-world analysis of erenumab in refractory chronic migraine

Giorgio Lambru et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Editorial Material Clinical Neurology

Combination therapy in migraine: asset or issue?

Paolo Martelletti

EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)

添加到收藏夹

Review Clinical Neurology

What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group

Simona Sacco et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)

添加到收藏夹

Article Clinical Neurology

Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?

Rosaria Greco et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Article Clinical Neurology

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data

David W. Dodick et al.

CEPHALALGIA (2019)

添加到收藏夹

Article Clinical Neurology

CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA

R. Moreno-Mayordomo et al.

JOURNAL OF HEADACHE AND PAIN (2019)

添加到收藏夹

Article Clinical Neurology

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

Peter J. Goadsby et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

添加到收藏夹

Article Clinical Neurology

Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment

Francesca Schiano di Cola et al.

FRONTIERS IN NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience

Fabrizio Vernieri et al.

HEADACHE (2019)

添加到收藏夹

Article Clinical Neurology

Prognosis Following Discontinuation of OnabotulinumA Therapy in Super-responding Chronic Migraine Patients

Jason Ching et al.

HEADACHE (2019)

添加到收藏夹

Article Clinical Neurology

Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine

Paul K. Winner et al.

HEADACHE (2019)

添加到收藏夹

Article Clinical Neurology

Migraine Epidemiology, Burden, and Comorbidity

Rebecca C. Burch et al.

NEUROLOGIC CLINICS (2019)

添加到收藏夹

Article Clinical Neurology

OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study

C. Dominguez et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study

Clara Dominguez et al.

HEADACHE (2018)

添加到收藏夹

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine

James E. Frampton et al.

DRUGS (2018)

添加到收藏夹

Letter Clinical Neurology

Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A

C. Dominguez et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

添加到收藏夹

Article Anesthesiology

Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns

Daniela Buonvicino et al.

PAIN (2018)

添加到收藏夹

Article Clinical Neurology

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

Lars Bendtsen et al.

JOURNAL OF HEADACHE AND PAIN (2018)

添加到收藏夹

Article Clinical Neurology

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

Todd Schwedt et al.

JOURNAL OF HEADACHE AND PAIN (2018)

添加到收藏夹

Article Clinical Neurology

A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience

Andrea Negro et al.

JOURNAL OF HEADACHE AND PAIN (2016)

添加到收藏夹

Article Clinical Neurology

Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study

Mi Ji Lee et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)

添加到收藏夹

Article Anesthesiology

OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine

Eva Cernuda-Morollon et al.

PAIN (2015)

添加到收藏夹

Article Clinical Neurology

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

Stephen D. Silberstein et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)

添加到收藏夹

Article Clinical Neurology

CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine

Eva Cernuda-Morollon et al.

HEADACHE (2014)

添加到收藏夹

Review Clinical Neurology

Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review

Michel Lanteri-Minet et al.

CEPHALALGIA (2011)

添加到收藏夹

Article Clinical Neurology

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program

Sheena K. Aurora et al.

HEADACHE (2011)

添加到收藏夹

Article Clinical Neurology

Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers

Milena De Felice et al.

BRAIN (2010)

添加到收藏夹

Article Clinical Neurology

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

H. C. Diener et al.

CEPHALALGIA (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.